Indeed all your points are valid, however; what is the game plan going forward?
What is the "road map for the future"? Where are they going to make their money?
As you know revenues and earnings drive stock prices. Why should we believe that the stumbling and bumbling with the marketing of Laviv is going to stop immediately and reverse course over-night into credible product that has a "place among the stars" when it hasn't shown much in 18 months post FDA-approval.
You sound like a decent fellow, but; after all: "one thousand artificial flowers will not make a desert bloom, likewise; one thousand empty faces will not fill an empty room."
Why should we believe you are not another from a long line "silver tongue pumpers" -- like the former "guru Mukinaki" sent to "drive cattle to the slaughter-house".
Since FDA approval of Laviv, management has received millions upon millions of financing dollars, with nary a wrinkle to show for it. What makes the recent hubbub any different from the previous financing.
So, after all of your cool blah, blah, blah, blah... as honestly as you can: please tell us just one simple thing. What has changed in management's strategic and tactical direction, as they struggle to tackle issues of: weaknesses, opportunities, threats and strengths? We seek "edifying eloquence" rather than pomp, please.